Search-and-replace gene editing
Prime Medicine is developing prime editing therapeutics — the most precise form of gene editing that can make any small edit without double-strand breaks. Founded on David Liu's prime editing technology.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| PM359 | Chronic Granulomatous Disease | Preclinical | Prime Editing |
| PM-Liver | Liver metabolic diseases | Preclinical | Prime Editing |
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.